Health knowledge made personal
Join this community!
› Share page:
Search posts:

Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus

Posted May 31 2007 5:00pm

Description of Invention:
Gene therapy and gene transfer have recently been recognized as effective therapeutic tools to combat diseases. Accordingly, market demands for vectors and carriers to facilitate such interventions have surged in recent years. Retroviral vectors provide an efficient and safe means of gene transfer to eukaryotic cells. The present invention relates to genetic engineering involving retrovirus packaging cells that produce retroviral vectors. Specifically, the invention involves the expression plasmids encoding the envelop glycoproteins of a family of primate type C retrovirus, namely, the Gibbon Ape leukemia virus (GALV). Recombinant vectors derived from murine leukemia virus (MLV) have been widely used to introduce genes in human gene therapy clinical trials. A key determinant for their use in clinical gene therapy is the availability of packaging cell lines capable of producing large amounts of virus with identical titers. The present invention describes the packaging cell lines that produce MLV-based gene transfer vectors with the envelope from gibbon ape leukemia virus. Retroviral vectors produced are of high titer and have an expanded host range providing a means for gene transfer to a wide range of animal species. The gene transfer vectors produced are non-infectious and there was no evidence of production of helper virus, making these vectors safe. These cell lines are critical for producing large amounts of standardized vector necessary for efficient for in vivo and ex vivo gene transfer. Therefore, this invention has a significant commercial application as a tool in the development of diagnostic and therapeutic interventions related to gene transfer and gene therapy.

Maribeth V Eiden (NIMH)

Patent Status:
HHS, Reference No. E-201-1991/0
US, , Patent No. 5,470,726, Issued 28 Nov 1995

Licensing Status:
Available for non-exclusive licensing.

Collaborative Research Opportunity:
The National Institute of Mental Health, Laboratory of Cellular and Molecular Regulation, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the Gibbon Ape leukemia virus (GALV) packaging cell line. Please contact Suzanne Winfield at for more information.

Gene Based Therapies
Gene Based Therapies - Research Materials
Internal Medicine
Internal Medicine - Research Materials

For Additional Information Please Contact:
Fatima Sayyid MHPM
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Phone: 301-435-4521
Fax: 301-402-0220

Ref No: 1549

Updated: 06/2007

Post a comment
Write a comment:

Related Searches